1-7 of 7
Karl-Heinz Heider, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD
Journal: Blood
Blood (2016) 128 (22): 2767.
https://doi.org/10.1182/blood.V128.22.2767.2767
Published: 2016
Journal Articles

Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody

Erika A Eksioglu, PhD, Karl-Heinz Heider, PhD, Bjoern Rueter, MD, Alexis Burnette, Max Wei, Kathy McGraw, Ashley A Basiorka, Parthik Patel, Jeffrey Lancet, Rami Komrokji, MD, Alan F. List, MD, Sheng Wei, MD
Journal: Blood
Blood (2014) 124 (21): 4597.
https://doi.org/10.1182/blood.V124.21.4597.4597
Published: 2014
Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2014) 124 (21): 4681.
https://doi.org/10.1182/blood.V124.21.4681.4681
Published: 2014
Journal Articles

Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy

Shun He, PhD, Carolyn Cheney, Susan P. Whitman, PhD, Jianhua Yu, PhD, Sumithira Vasu, MBBS, William Blum, MD, Karl-Heinz Heider, PhD, Guido Marcucci, MD, Natarajan Muthusamy, DVM, Ph.D
Journal: Blood
Blood (2013) 122 (21): 3959.
https://doi.org/10.1182/blood.V122.21.3959.3959
Published: 2013
Journal Articles

A Novel Fc-Engineered Antibody to CD33 with Enhanced ADCC Activity for Treatment of AML

Karl-Heinz Heider, PhD, Renate Konopitzky, PhD, Elinborg Ostermann, PhD, Herbert Lamche, PhD, Zaruhi Kuepcue, PhD, Christian Koessl, Ph.D., Paul Adam, Ph.D., Eric Borges, PhD
Journal: Blood
Blood (2012) 120 (21): 1363.
https://doi.org/10.1182/blood.V120.21.1363.1363
Published: 2012
Journal Articles

Novel Fc-Engineered Antibodies to CD37 with Pro-Apoptotic and Enhanced ADCC Activity

Karl-Heinz Heider, PhD, Elinborg Ostermann, PhD, Herbert Lamche, PhD, Zaruhi Kuepcue, PhD, Alexander Jacobi, PhD, Renate Konopitzky, PhD, Ulrich Hirt, PhD, Volker Reichardt, MD, Eric Borges, PhD
Journal: Blood
Blood (2010) 116 (21): 3916.
https://doi.org/10.1182/blood.V116.21.3916.3916
Published: 2010
Journal Articles

Exceptional In Vitro Activity of CD37 Antibodies In CLL

Thorsten Zenz, MD, Matthias Volden, Theresa Mast, Karsten Nordhausen, Dirk Winkler, MD, Andrea Schnaiter, MD, Andreas Buehler, MD, Karl-Heinz Heider, PhD, Volker Reichardt, MD, Hartmut DoĢˆhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2010) 116 (21): 2460.
https://doi.org/10.1182/blood.V116.21.2460.2460
Published: 2010